Childhood Acute Monoblastic Leukemia (M5a) Clinical Trial
Official title:
Observational - Rapid Identification of Leukemia Stem Cells Associated With AML1-ETO and Inv(16) Through Characterization of Oncogene-Induced Changes in Cell-Surface Antigen Profiles on Hematopoietic Stem Cells
This laboratory study is looking into biomarkers in samples from younger patients with acute myeloid leukemia. Studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer
Study Subtype: Observational Observational Study Model: Case-control Time Perspective:
Retrospective Biospecimen Retention: Samples With DNA Biospecimen Description: Cryopreserved
bone marrow samples Study Population Description: Patient samples with the AML1-ETO
translocation and cytologically normal AML samples for controls Sampling Method:
Non-Probability Sample
OBJECTIVES:
I. To address whether the mutation-specific cell-surface markers observed in murine system
will allow the prospective isolation of leukemia stem cells (LSC) from human bone marrow
samples that have the same cytogenetic abnormalities.
II. To compare the incidence of leukemia in NSG mice that have received CD34+CD38 marker+
cells to NSG mice that receive what are hypothesized to be normal cells (CD34+CD38
marker-subset) from the same patient.
OUTLINE:
Samples and controls are sorted and re-sorted for CD34, CD38, and CD55 subsets by
single-cell polymerase chain reaction (PCR) analysis, flow cytometry, and
reverse-transcriptase PCR. Sorted cell subsets are then transplanted into NSG mice.
Beginning 6 weeks after transplantation, peripheral blood samples are collected and analyzed
for human lymphoid- and myeloid-lineage cells by fluorescence-activated cell sorting (FACS).
;
Observational Model: Case Control, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01093586 -
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
| Recruiting |
NCT01146210 -
Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
|
N/A | |
| Terminated |
NCT00096148 -
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
|
Phase 2 | |
| Completed |
NCT00006363 -
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
|
Phase 3 | |
| Terminated |
NCT01801046 -
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
|
Phase 1 | |
| Completed |
NCT01076569 -
Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia
|
N/A | |
| Completed |
NCT00369317 -
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
|
Phase 3 | |
| Completed |
NCT01177371 -
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
|
Phase 2 | |
| Completed |
NCT00002798 -
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
|
Phase 3 | |
| Completed |
NCT00666588 -
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
|
Phase 2 |